The Centre for Outcomes Research and Economic Evaluation for Health (C2H) is an esteemed department of the National Institute of Public Health in Japan, established in 2018. The organisation conducts rigorous academic research on cost-effectiveness evaluations and plays a crucial role in the official evaluation process. In a nation where public healthcare expenditure is continually increasing, C2H’s work is invaluable. They strive to balance the cost and outcome of healthcare technologies, providing crucial data and materials for evidence-based health policy. The ultimate goal is to enhance the sustainability of the public healthcare system. C2H is a beacon of knowledge for experts conducting cost-effectiveness evaluations, offering guidelines and analytical tools. Furthermore, they also guide manufacturers in conducting scientifically sound analyses and help citizens and healthcare professionals understand the value and implications of their evaluations. Below are some insights to Valbenazine market access.
In May 2023, Valbenazine was reimbursed and its drug price was set at JPY 2331.2 for a Dysval® capsule 40mg in Japan, determined via the Similar Efficacy Comparison Method with a 5% premium. This pricing strategy is an example of dynamic pricing, a common practice in pharmaceutical pricing strategy. The drug was designated for the Cost-effectiveness Evaluation with an H2 classification, reflecting its significant value story.
The target population for Valbenazine is patients with tardive dyskinesia whose symptoms have not improved sufficiently by reducing or discontinuing drugs for underlying diseases. Given the limited treatment options for this group, the comparator for the cost-effectiveness evaluation was “watchful waiting”.
The manufacturer conducted a systematic review of randomised controlled trials to evaluate the drug’s additional benefits. This review included a mixed-model meta-analysis that compared Valbenazine with a placebo. The results showed that Valbenazine significantly improved patients’ symptoms. This reaffirms the value-based healthcare benefits of the drug.
The manufacturer conducted a cost-utility analysis using a microsimulation model. This model accounted for responses from interventions, prescription of antipsychotic drugs, and recurrence of underlying diseases. Interestingly, the results of this analysis further substantiated the benefits of Valbenazine, demonstrating its cost-effectiveness and aligning with the principles of value-based healthcare 2024.
🌍 Today is World Diabetes Day! Managing diabetes effectively is key to a healthier life! Discover strategies for preoperative risk assessment, obesity management, and safe fasting during Ramadan. Let’s prioritise our health together! 💪
#SyenzaNews #WorldDiabetesDay #DiabetesManagement #RamadanFasting #ObesityManagement
🌍 How can self-collection methods improve cervical cancer screening?
A recent article from the National Cancer Institute explores the groundbreaking FDA approval for HPV tests that allow patients to safely collect their own vaginal samples in a healthcare setting. This innovation promises to enhance access to screening for underserved populations and could transform the future of cervical cancer prevention. Jump into the details and learn how this initiative is poised to address health disparities in the U.S.
#SyenzaNews #oncology #HealthcareInnovation #HealthTech #innovation
🌍 How can we combat the rising threat of Antimicrobial Resistance (AMR) in Africa?
The new guidance from Africa CDC presents a comprehensive framework for strengthening AMR surveillance. By implementing a One Health approach and enhancing collaboration, we can address the challenges posed by AMR and significantly improve public health outcomes across the continent.
Jump into the details of this critical initiative and discover how we can work together to forge a sustainable path forward!
#SyenzaNews #GlobalHealth #HealthcareInnovation #DataScience #AMR #OneHealth
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
